OTCPK:SPGR.F

Stock Analysis Report

Executive Summary

SpineGuard SA provides spine surgery products.

Snowflake

Fundamentals

Worrying balance sheet with weak fundamentals.

Risks

  • SpineGuard is not covered by any analysts.

Share Price & News

How has SpineGuard's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:SPGR.F

-1.2%

US Medical Equipment

1.2%

US Market


1 Year Return

n/a

OTCPK:SPGR.F

8.7%

US Medical Equipment

1.7%

US Market

No trading data on SPGR.F.

No trading data on SPGR.F.


Share holder returns

SPGR.FIndustryMarket
7 Day0%-1.2%1.2%
30 Day0%1.4%4.9%
90 Day0%4.8%3.7%
1 Yearn/a9.6%8.7%3.9%1.7%
3 Yearn/a70.8%65.5%47.2%37.7%
5 Yearn/a130.4%104.1%60.0%42.4%

Price Volatility Vs. Market

How volatile is SpineGuard's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is SpineGuard undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether SpineGuard is trading at an attractive price based on the cash flow it is expected to produce in the future. But as SpineGuard has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of SPGR.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through SpineGuard regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is SpineGuard expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SpineGuard has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of SPGR.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access SpineGuard's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has SpineGuard performed over the past 5 years?

6.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

SpineGuard does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare SpineGuard's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare SpineGuard's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if SpineGuard has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if SpineGuard has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if SpineGuard improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is SpineGuard's financial position?


Financial Position Analysis

SpineGuard's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

SpineGuard's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

SpineGuard has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if SpineGuard's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

SpineGuard has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

SpineGuard has less than a year of cash runway based on current free cash flow.

SpineGuard has less than a year of cash runway if free cash flow continues to reduce at historical rates of -24.5% each year.


Next Steps

Dividend

What is SpineGuard's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate SpineGuard's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate SpineGuard's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as SpineGuard has not reported any payouts.

Unable to verify if SpineGuard's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as SpineGuard has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of SpineGuard's salary, the management and board of directors tenure and is there insider trading?

5.8yrs

Average management tenure


CEO

Stéphane Bette 0

1.9yrs

Tenure

€155,522

Compensation

Mr. Stéphane Bette co-founded SpineGuard Société Anonyme in January 2009 and has been its Chief Executive Officer since July 13, 2017. Mr. Bette served Chief Technology Officer of SpineGuard Société Anonym ...


CEO Compensation Analysis

Stéphane's remuneration is lower than average for companies of similar size in United States of America.

Insufficient data for Stéphane to compare compensation growth.


Management Age and Tenure

5.8yrs

Average Tenure

The average tenure for the SpineGuard management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

9.0yrs

Average Tenure

The tenure for the SpineGuard board of directors is about average.


Insider Trading

No 3 month insider trading information.


Ownership Breakdown


Management Team

  • Pierre Jérôme

    Co-Founder & Chairman of the Board

    • Tenure: 1.2yrs
    • Compensation: €194.92k
  • Stéphane Bette

    Co-Founder

    • Tenure: 1.9yrs
    • Compensation: €155.52k
  • Maurice Bourlion

    Director & Co-Inventor

    • Tenure: 9.9yrs
  • Steve McAdoo

    General Manager of USA

    • Tenure: 3.4yrs
  • Manuel Lanfossi

    Chief Financial Officer

    • Tenure: 8.2yrs

Board Members

  • Alan Olsen (71yo)

    Director

    • Tenure: 9yrs
    • Compensation: €55.42k
  • Alexia Perouse (46yo)

    Director

    • Tenure: 0yrs
  • Joe Mason

    Director

    • Tenure: 9.9yrs
  • Pierre Jérôme

    Co-Founder & Chairman of the Board

    • Tenure: 1.2yrs
    • Compensation: €194.92k
  • Stéphane Bette

    Co-Founder

    • Tenure: 1.9yrs
    • Compensation: €155.52k
  • Maurice Bourlion

    Director & Co-Inventor

    • Tenure: 9.9yrs

Company Information

SpineGuard SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: SpineGuard SA
  • Ticker: SPGR.F
  • Exchange: OTCPK
  • Founded: 2009
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €2.941m
  • Listing Market Cap: €3.329m
  • Shares outstanding: 6.70m
  • Website: https://www.spineguard.com

Number of Employees


Location

  • SpineGuard SA
  • 10, Cours Louis Lumière
  • Vincennes
  • Ile-de-France
  • 94300
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALSGDENXTPA (Euronext Paris)YesCommon StockFREURApr 2013
SPGR.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDApr 2013

Biography

SpineGuard SA provides spine surgery products. The company’s PediGuard products are handheld devices that detect possible vertebral cortex perforation during pedicle preparation for screw placement, and al ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/06/13 01:06
End of Day Share Price2019/03/15 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.